Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.07
+0.25 (3.67%)
May 29, 2026, 4:00 PM EDT - Market closed
Entrada Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $19.5. The average 1-year stock price forecast is 175.81% higher than the current stock price, while the lowest is $10 (+41.44%) and the highest is $25 (+253.61%).
Price Target: $19.5 (+175.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 7 | 8 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Buy Reiterates $10 | Buy | Reiterates | $10 | +41.44% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $25 | Buy | Maintains | $25 | +253.61% | May 5, 2026 |
Financial Forecast
Revenue This Year
22.15M
from 25.42M
Decreased by -12.88%
Revenue Next Year
46.79M
from 22.15M
Increased by 111.28%
EPS This Year
-4.07
from -3.47
EPS Next Year
-3.75
from -4.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 89.3M | ||||||
| Avg | 22.1M | 46.8M | ||||||
| Low | n/a | 3.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 147.8% | 303.0% | ||||||
| Avg | -12.9% | 111.3% | ||||||
| Low | - | -84.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.81 | -2.31 | ||||||
| Avg | -4.07 | -3.75 | ||||||
| Low | -4.40 | -4.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.